Eledon Pharmaceuticals Inc Aktie News

IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.

Eledon Reports Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation

Eledon Pharmaceuticals, Inc. ( ELDN ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 12, 2025 10:30 AM EST Company Participants Steven Perrin - President, Chief Scientific Officer & Non Independent Director Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Presentation Vamil Divan Guggenheim Securities, LLC, Research Division Al...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus  Data supports advancement into Phase 3 development as a potential new standard for the prevention of kidney transplant rejection Strengthened balance sheet with $57.5 million financing to adv...

IRVINE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten public offering of (i) 15,152,485 shares of its common stock at a public offering price of $1.65 per share and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 15,151,515 shares of common...

IRVINE, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock.

Eledon Pharmaceuticals, Inc. ( ELDN ) Discusses Phase II BESTOW Trial Results and Advances in Transplantation Immunosuppression November 7, 2025 8:00 AM EST Company Participants David-Alexandre Gros - CEO & Non Independent Director Eliezer Katz - Chief Medical Officer Steven Perrin - President, Chief Scientific Officer & Non Independent Director Paul Little - Chief Financial Officer Conference ...

Data from patients who remained on tegoprubart for a year post transplant showed an overall mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m²  Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus Supports advancement into...